Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays

Sangamo Therapeutics (NASDAQ:SGMO - Free Report) had its target price increased by Barclays from $3.00 to $9.00 in a report released on Thursday,Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company's stock.

SGMO has been the topic of a number of other reports. HC Wainwright raised their price target on Sangamo Therapeutics from $5.00 to $10.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. StockNews.com started coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a "sell" rating on the stock.

Sangamo Therapeutics Trading Down 11.9 %

NASDAQ SGMO traded down $0.29 on Thursday, hitting $2.15. 7,610,567 shares of the stock traded hands, compared to its average volume of 6,930,090. The stock has a 50-day moving average of $1.30 and a 200 day moving average of $0.85. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The company has a market capitalization of $447.68 million, a P/E ratio of -2.87 and a beta of 1.10.

Institutional Investors Weigh In On Sangamo Therapeutics

Hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC raised its holdings in shares of Sangamo Therapeutics by 4.0% during the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock worth $3,311,000 after acquiring an additional 192,385 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock valued at $1,479,000 after purchasing an additional 1,528,600 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company's stock worth $956,000 after acquiring an additional 57,125 shares during the last quarter. Marshall Wace LLP grew its holdings in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock valued at $207,000 after buying an additional 207,476 shares in the last quarter. Finally, FMR LLC increased its position in Sangamo Therapeutics by 16.5% during the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company's stock worth $471,000 after acquiring an additional 77,032 shares during the period. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.